Ceregene

Ceregene is a privately held biotechnology company based in San Diego, specializing in the treatment of major neurodegenerative disorders through the delivery of nervous system growth factors. The company's clinical programs feature CERE-110, an AAV2-based vector expressing nerve growth factor, which is set to enter Phase 2 studies for Alzheimer's disease. Additionally, CERE-120 has recently completed a Phase 2 trial for Parkinson's disease and is under evaluation for future development. Ceregene is also advancing two other treatments, CERE-135 and CERE-140, which are in preclinical stages targeting amyotrophic lateral sclerosis (ALS) and ocular diseases, respectively.